Subsidiary RPGAP to acquire Raghava Life Sciences API business for up to Rs 135 cr

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

RPGLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.7%Reaction day

₹2565.10

prior close

₹2596.90

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.6%+3.1% vs market

Pharmaceuticals peers, median of 172sector+0.3%+3.3% vs sector

On the reaction day the stock moved 3.1 pts more than Nifty Microcap 250 and 3.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.5

10m

+0.1

15m

-0.5

30m

+1.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.7+0.6+3.1+0.3+3.3

Next day

+6.0+1.3+4.8+0.2+5.8

+3.9+1.7+2.2+0.8+3.1

+11.1+2.2+8.9+1.1+10.0

+9.0+2.1+6.9+0.6+8.4

+8.4+1.9+6.5+0.8+7.6

+8.0-1.3+9.3-1.1+9.1

15d

+19.1+1.3+17.8+0.8+18.3

+13.3-0.8+14.1-2.2+15.5

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

RPG Active Pharma (RPGAP), a wholly owned subsidiary of RPG Life Sciences, will acquire the API and intermediates business of Raghava Life Sciences via slump sale for up to Rs 135 crore. The deal adds a WHO-GMP and EU-GMP approved Hyderabad facility with about 300 KL capacity, 22 commercialized APIs, 7 in development, and approvals like CEP, EU Written Confirmation and KDMF. This is RPGAP's second acquisition after Actis Generics, funded by a recent equity raise.

Likely market impact

Positive for growth — strengthens API business with added capacity, portfolio and regulatory approvals; expands integrated API strategy.